9 Amendments of Rosa ESTARÀS FERRAGUT related to 2016/2057(INI)
Amendment 16 #
Draft opinion
Recital C
Recital C
C. whereas the WTO Doha Declaration on the TRIPS Agreement and Public Health acknowledges the role ofrecognises that intellectual property protection ins important for the development of new medicines, while expresrecognising concerns about its effects on prices;
Amendment 25 #
Draft opinion
Recital E
Recital E
E. whereas the rationale ofor patent rights is to make investment in innovation possible and attractive and to ensure that the knowledge contained in patent applications is accessible;
Amendment 32 #
Draft opinion
Paragraph 1
Paragraph 1
1. Highlights the fact that the WTO TRIPS Agreement provides flexibilities to patent rights, such as compulsory licensing, which have proved to be a major tool in bringing prices to reasonable levelcan be used as an effective tool in exceptional circumstances established by the law of each WTO member to address public health problems;
Amendment 41 #
Draft opinion
Paragraph 2
Paragraph 2
2. Considers that exclusive protection periods granted to pharmaceuticals through patents or other mechanisms hinder competition, lead to high prices and negatively impact access to needed medicineare an important tool to encourage R&D and provide incentives to innovation; acknowledges, at the same time, the importance of promoting competition and preventing cases of market abuse, as well as the need of ensuring access to needed medicines at affordable prices and guaranteeing the sustainability of national healthcare systems;
Amendment 52 #
Draft opinion
Paragraph 3
Paragraph 3
3. Recalls that the Pharmaceutical Sector Inquiry Report adoptled by the Commission in 2009 showed that manufacturindicated a numbers of medicines have developed abusive strategies in connection withproblems in companies' practices that, among other factors such as shortcomings in the regulatory framework, paotent claims in order to hinderially contribute to delays to the market entry of generic medicines, which should be avoided and emphasised the importance of stronger competition law enforcement;
Amendment 63 #
Draft opinion
Paragraph 4
Paragraph 4
4. Calls on the Commission to undertake a critical review of the impact of intellectual-property-related incentives on biomedical innovation, to explore effective alternatives to monopoliepatents for the financing of medical R&D and to evaluate the functioning of the applicable limitations to patent allocationrights;
Amendment 71 #
Draft opinion
Paragraph 5
Paragraph 5
5. Calls on the European Patent Office (EPO) and the Member States to continue to grant patents on health products that strictly fulfil the patentability requirements of novelty, inventive step and industrial applicability as enshrined in the European Patent Convention;
Amendment 77 #
Draft opinion
Paragraph 6
Paragraph 6
6. Calls on the Commission to encourage Member States to fully implement existing patent limitations and flexibilities when confronted with excessive pricing or abuse of monopoly rightin duly justified cases, such as cases of national emergencies, other circumstances of extreme urgency or anti- competitive practices;
Amendment 82 #
Draft opinion
Paragraph 7
Paragraph 7
7. Calls on the Commission and the Member States to establish full transparency on the results of publicly financed R&D so that patenting and licensing conditions guarantee a public health return on public investments and reflect the structure of R&D funding.